Neuland Laboratories

Neuland Laboratories Gross Margin

The Gross Margin of Neuland Laboratories (NEULANDLAB.NS) as of Oct 28, 2026 is 31.78 %. In the previous year, Gross Margin was 47.68 % — a change of -33.33% (lower).

Gross Margin

31.78 %

YoY

-33.33%

Last updated:

Gross Margin of Neuland Laboratories is 2026 31.78 % . Gross Margin of Neuland Laboratories was 2025 47.68 % . It decreases by -33.33% lower compared to the previous year.

For Neuland Laboratories, the gross margin of 31.8% is down versus 40.1% a few years ago.

The Neuland Laboratories Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2019
38.60 INR
Jan 1, 2020
45.34 INR
Jan 1, 2021
39.58 INR
Jan 1, 2022
40.05 INR
Jan 1, 2023
47.13 INR
Jan 1, 2024
51.59 INR
Jan 1, 2025
47.68 INR
Jan 1, 2026
31.78 INR
The Neuland Laboratories Gross Margin history
YEARGross MarginYoY
31.78 %-33.33%
47.68 %-7.58%
51.59 %+9.46%
47.13 %+17.66%
40.05 %+1.19%
39.58 %-12.69%
45.34 %+17.44%
38.60 %-10.79%
43.27 %-23.59%
56.63 %+7.47%
52.69 %+12.55%
46.82 %-3.81%
48.67 %+11,707.38%
0.41 %+16.75%
0.35 %-3.95%
0.37 %+37.38%
0.27 %-1.01%
0.27 %+143.68%
0.11 %-51.71%
0.23 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Neuland Laboratories Stock analysis

What does Neuland Laboratories do? Neuland Laboratories Ltd. generates revenue through the manufacture and export of bulk pharmaceutical ingredients and intermediates for the generics industry. The company operates in a single segment focused on active pharmaceutical ingredients (APIs) and allied services, with two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, and Labetalol, which are supplied to both domestic and international markets. The firm provides end-to-end chemistry solutions for the pharmaceutical industry, covering synthesis of library compounds, NCEs, and advanced intermediates across clinical and commercial stages. The company's primary customers are pharmaceutical firms requiring APIs and intermediates for generic drugs, with a focus on global markets. Neuland Laboratories Ltd. serves as a solution provider for chemistry needs, offering services from early-stage development to commercial production. The business model emphasizes tailored manufacturing services under CMS, alongside standardized GDS products, catering to the full lifecycle of pharmaceutical development and production. Revenue streams are derived from the sale of specific APIs like Levetiracetam and Mirtazapine, as well as custom manufacturing services for complex chemical processes. The firm's dual verticals allow it to address diverse market demands, with GDS targeting cost-effective generic drug production and CMS focusing on specialized, high-value manufacturing solutions for pharmaceutical clients. Neuland Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuland Laboratories stock

Gross Margin of Neuland Laboratories is 31.78 % in 2026.

Gross Margin of Neuland Laboratories changed from 47.68 % to 31.78 %, representing a -33.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Neuland Laboratories since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Neuland Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Neuland Laboratories

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Neuland Laboratories